The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic?
Open accessAbstract
Background: Beliefs of dementia experts about the pathogenic role of amyloid in Alzheimer's disease (AD) may affect the use of amyloid positron emission tomography (PET). Objective: To assess the role attributed to amyloid in AD pathogenesis by Italian dementia experts, and whether this modulates the impact of amyloid PET results in their diagnostic workup. Methods: 22 dementia experts rated their beliefs about the pathogenic role of amyloid. Then, we asked them to rate the probability of change in diagnosis based on the result of amyloid PET for 7 case vignettes, depicting patients who initially received a diagnosis based on a comprehensive workup and later received amyloid PET results consistent or inconsistent with the clinical picture. Results: 55% of the experts assigned a dominant role to amyloid, and 32% attributed a similar role to amyloid and tau in AD pathogenesis. The probability of change in diagnosis ranged from 17% (SD = 21.6) for cases with consistent to 51% (SD = 34) for cases with inconsistent PET versus clinical data. Diagnostic change was not biased by the clinicians' beliefs about AD pathogenesis. Conclusions: This work supports an unbiased interpretation of amyloid PET across different beliefs about the pathogenic role of amyloid, and a belief-independent reluctance to change diagnosis in cases where change is expected and recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Amyloid PET has been established as an important imaging tool in the early, specific and unbiased diagnosis of AD [153–155].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [153]
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Linear Mixed Models: A Practical Guide Using Statistical Software
West, B. T., Welch, K. B., & Gałecki, A. T. (2006) · Thammasat University Digital Collections · Cited by 1,382
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Clark, C. M., Pontecorvo, M. J., Beach, T. G., Bedell, B. J., Coleman, R. E., Doraiswamy, P. M., Fleisher, A. S., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70142-4 · Cited by 855
Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602
Alzheimer's disease – do tauists and baptists finally shake hands?
Mudher, A., & Lovestone, S. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02031-2 · Cited by 514
Gut Feelings as a Third Track in General Practitioners’ Diagnostic Reasoning
Stolper, E., Van de Wiel, M., Van Royen, P., Van Bokhoven, M., Van der Weijden, T., & Dinant, G. J. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1524-5 · Cited by 265
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V., Vemuri, P., Mielke, M. M., Jones, D. T., Senjem, M. L., Gunter, J. L., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000435556.21319.e4 · Cited by 199
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L. H., Wolfs, C. A. G., Aalten, P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.07.003 · Cited by 194
Cited by
The use of neuroimaging techniques in the early and differential diagnosis of dementia
Chouliaras, L., & O’Brien, J. T. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02215-8 · Cited by 221
“Amyloid PET has been established as an important imaging tool in the early, speci fi c and unbiased diagnosis of AD [153 – 155].”
MethodClinical Use and Utility of Amyloid Imaging
Barthel, H., & Sabri, O. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185017 · Cited by 103
“Of interest with regard to the amyloid cascade theory and the fact that there exist alternative theories of AD pathogenesis, such as the one claiming that tau aggregation is the cascade trigger, it was recently reported that the interpretation of amyloid images is not affected by belief about the pathogenic role of am…”
BackgroundBoccardi, M., Altomare, D., Ferrari, C., Festari, C., Guerra, U. P., Paghera, B., Pizzocaro, C., Lussignoli, G., Geroldi, C., Zanetti, O. O., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3751 · Cited by 98
Self-citationAMYPAD Diagnostic and Patient Management Study: Rationale and design
Frisoni, G. B., Barkhof, F., Altomare, D., Berkhof, J. H., Boccardi, M., Canzoneri, E., Collij, L. E., Drzezga, A. E., Farrar, G., Garibotto, V., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.003 · Cited by 55
“Assuming that the physicians’ beliefs on the pathophysiological role of amyloid in neurodegenerative diseases [46] can affect the disclosure of amyloid-associated risk, the managing physicians’ beliefs will be recorded as well by asking them to fill in a questionnaire.”
BackgroundSelf-citationIncremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease
Ramusino, M. C., Garibotto, V., Bacchin, R. A., Altomare, D., Dodich, A., Assal, F., Mendes, A., Costa, A. C., Tinazzi, M., Morbelli, S. D., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04466-6 · Cited by 32
Self-citation
Metadata
- Authors
- Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Antelmi, L., Pievani, M., Tarallo, A., Muscio, C., Guerra, U. P., Paghera, B., Padovani, A., Frisoni, G. B., & and the INDIA-FBP Working Group
- Affiliations
- University of Brescia (IT)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- University of Geneva (CH)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- ORCID
- Venue
- Neurodegenerative Diseases
- Publisher
- S. Karger AG
- Published
- 2015-12-01
- Volume
- 16
- Issue
- 1-2
- Pages
- 111-117
- ISSN
- 1660-2854 (ISSN-L)
- 1660-2862
- OpenAlex
- W2233552060
- Cited by
- 7
- References
- 19
- Citations by year
- 2023: 1 · 2022: 1 · 2021: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2016: 1
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Neurodegenerative Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Family Practice › Clinical Reasoning and Diagnostic Skills
- Keywords
- amyloid PET, Alzheimer's disease pathogenesis, amyloid, clinician beliefs, diagnostic change, dementia diagnosis, tau protein, case vignettes, diagnostic bias
- MeSH terms
- Alzheimer Disease, Amyloid, Attitude of Health Personnel, Diagnosis, Differential, Humans, Italy, Physicians, Pilot Projects, tau Proteins, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic? https://app.cochat.ai/papers/10.1159/000439255
- The paper
- Boccardi, M., Altomare, D., Ferrari, C., Festari, C., Antelmi, L., Pievani, M., Tarallo, A., Muscio, C., Guerra, U. P., Paghera, B., Padovani, A., Frisoni, G. B., & and the INDIA-FBP Working Group. (2016). Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic? Neurodegenerative Diseases. https://doi.org/10.1159/000439255
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.